PDGFRB and neoplasm: Nilotinib is currently being investigated for repurposing to determine its potential therapeutic benefits in other conditions, particularly in tumours with KIT or PDGFR alterations, including gastrointestinal stromal tumours (GIST) and melanoma, where early studies have shown encouraging results [81,82,83,84].